BioSpace News Archive

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), today announced that it will present new data for reloxaliase, its first-in-class, oral enzyme for the treatment of hyperoxaluria, and for ALLN-346, its first-in-class, oral enzyme for the treatment of hyperuricemia in the setting of advanced chronic kidney disease (CKD) at upcoming medical meetings in November 2019.

New patent-pending formula combines hemp extract with PEA to support bodily comfort*

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the special committee (the “Special Committee”) of the Company’s board of directors (the “Board”) has retained Duff & Phelps, LLC and Duff & Phelps Securities, LLC as its financial advisor and Davis Polk & Wardwell LLP

The contract is being awarded by the Department of Health and Human Services BARDA DRIVe initiative; Maternal sepsis is a leading cause of maternal mortality in the United States

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that it has completed enrollment in RIST4721-201, a Phase 2a study to evaluate the efficacy and safety of RIST4721 in patients with palmoplantar pustulosis.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that it will report financial results for the third quarter of 2019 after the market close on Thursday, November 7, 2019.

Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its latest molecular quality control panel.

Top Experts, Lawmakers and Advocates Come Together to Discuss Policy Solutions to Support Growing Number of Americans Living with Mental Illness

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company, today announced the launch of 1937 Cannabis, a new brand of professional grade cannabis-based products

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces that the first patient has been enrolled in its Phase 2 on-ambulance study evaluating trans sodium crocetinate (TSC) for the treatment of stroke.